A systematic review of genotypes and serogroups of African swine fever virus

African swine fever virus (ASFV) is the causative agent of African swine fever (ASF). The virus causes an acute highly hemorrhagic disease in domestic pigs, with high mortality. Although the overall genome mutation rate of ASFV, a large DNA virus, is relatively low, ASFV exhibits genetic and antigen...

Full description

Saved in:
Bibliographic Details
Published in:Virus genes Vol. 58; no. 2; pp. 77 - 87
Main Authors: Qu, Hailong, Ge, Shengqiang, Zhang, Yongqiang, Wu, Xiaodong, Wang, Zhiliang
Format: Journal Article
Language:English
Published: New York Springer US 01.04.2022
Springer Nature B.V
Subjects:
Adsorption
African Swine Fever
African swine fever virus
African Swine Fever Virus - genetics
Animals
antigenic variation
Asfarviridae
Biomedical and Life Sciences
Biomedicine
DNA viruses
etiological agents
genes
Genetic diversity
Genomes
Genotype
Genotypes
Genotyping
Hemadsorption
Hemorrhage
Hemorrhagic disease
Medical Microbiology
mortality
mutation rate
Mutation rates
Phylogeny
Plant Sciences
Review Paper
Serogroup
serotypes
Sus scrofa
Swine
systematic review
Virology
viruses
African swine fever virus
Genotype
Serogroup
ISSN:0920-8569, 1572-994X, 1572-994X
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:African swine fever virus (ASFV) is the causative agent of African swine fever (ASF). The virus causes an acute highly hemorrhagic disease in domestic pigs, with high mortality. Although the overall genome mutation rate of ASFV, a large DNA virus, is relatively low, ASFV exhibits genetic and antigenic diversity. ASFV can be classified into 24 genotypes on the basis of the B646L gene. Cross-protected ASFV strains can be divided into eight serogroups on the basis of antibody-mediated hemadsorption inhibition. Here, we review research progress on ASFV genotyping and serogrouping, and explain how this information assists in the rapid identification of virus origin during ASF outbreaks and will aid in the development of ASF vaccines.
Bibliography:ObjectType-Article-1
ObjectType-Evidence Based Healthcare-3
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ObjectType-Undefined-4
Edited by Juergen A Richt.
ISSN:0920-8569
1572-994X
1572-994X
DOI:10.1007/s11262-021-01879-0